MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System Therapeutics

MapLight Therapeutics, Inc. California

Funding will support development of multiple clinical candidates to treat neurological and psychiatric disorders, including Phase 2 studies for ML-007C-MA in 2024 in schizophrenia and Alzheimer's disease psychosisNovo Holdings led a group of top-tier, new investors including Cowen Healthcare Investments, 5AM Ventures and othersView original content:https://www.prnewswire.co.uk/news-releases/maplight-therapeutics-closes-225-million-series-c-funding-round-to-advance-pipeline-of-central-nervous-system-therapeutics-301970924.html